FS2 Safety and Tolerability Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
CicatrixCicatrix, HypertrophicKeloid
Interventions
DRUG

Acute Application of kynurenic acid cream

Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.

DRUG

Chronic application of kynurenic acid cream

Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30

Trial Locations (1)

V5Z1M9

BCPFF Burn & Wound Healing Lab, Vancouver

All Listed Sponsors
lead

British Columbia Professional Firefighters' Burn and Wound Healing Laboratory

OTHER

NCT02340325 - FS2 Safety and Tolerability Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter